Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab in moderately to severely active ulcerative colitis
NCT02520284Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of andecaliximab in ulcerative colitis (UC), sponsored by Gilead Sciences. Started Sep 2015; status: terminated.
02
Drugs
andecaliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02520284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520284.